Effect of 17-Hydroxyprogesterone Caproate on Interleukin-6 and Tumor necrosis factor-alpha in expectantly managed early-onset preeclampsia.

Autor:	Othman MA; Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt., Badawy ER; Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt., Sobh AMA; Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt., Shaltout AS; Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt., Mostafa SA; Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Jazyk:	angličtina
Zdroj:	The Egyptian journal of immunology [Egypt J Immunol] 2023 Apr; Vol. 30 (2), pp. 109-118.
Abstrakt:	The study aimed to evaluate the effect of 17 hydroxy progesterone (17-OHPC) on interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in expectantly managed early-onset preeclampsia (PE). A randomized open-label controlled study included women who were diagnosed as early-onset PE if they assigned to expectant management according to the American College of Obstetricians and Gynecologists (ACOG) 2013 criteria for diagnosis of severity of PE. Patients were randomized into Group A (40 patients) received 17-OHPC 250 mg intra-muscular at admission and every 7 days thereafter and Group B (40 patients) was given the usual conservative measures of early-onset PE as a control group. Blood samples were obtained from all participants for measurements of TNF-α and IL-6 levels at admission and repeated at termination of pregnancy. The primary outcome was the mean difference between TNF-α and IL-6 levels before and after treatment in both groups. TNF-α and IL-6 levels at admission were not different between the two groups. However, there was a significant difference concerning these inflammatory biomarkers within the same group at admission and at termination (p < 0.001), with significant decline of IL-6 and TNF-α level in the 17-OHPC treated group and significant rise of IL-6 and TNF-α in the control group. There was a strong positive correlation between systolic blood pressure (SBP) at admission and TNF-α level (r= 0.867, p=0.017), and moderately positive significant correlation between diastolic blood pressure (DBP) at admission and TNF-α (r=0.610, p < 0.001). There was a mild positive significant correlation between IL-6 levels and SBP (r= 0.231, p=0.039), and DBP (r= 0.203, p= 0.041) at admission. In conclusion, 17-OHPC has no effect in improving maternal or neonatal outcomes in conservatively managed early onset PE, although it alters the inflammatory markers levels (IL-6 and TNF-α) that could improve the pathogenesis of PE. (Copyright© by the Egyptian Association of Immunologists.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu